Patent ID: 11957748
Assignee: 21C BIO
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 7:
8. The method for preventing according to claim 1, wherein the CD8 vaccine is an active vaccine, and wherein the CD8 vaccine is a cytomegalovirus (CMV) vector comprising:
 a first nucleic acid sequence encoding at least one HIV antigen,
 optionally a second nucleic acid sequence comprising a first microRNA recognition element (MRE) operably linked to a CMV gene that is essential or augmenting for CMV growth, wherein the MRE silences expression in the presence of a microRNA that is expressed by a cell of endothelial lineage;
and wherein the CMV vector does not express an active UL128 protein or ortholog thereof; does not express an active UL130 protein or ortholog thereof; does not express an active UL146 or ortholog thereof; does not express an active UL147 protein or ortholog thereof,
and wherein the CMV vector expresses at least one active UL40 protein or an ortholog thereof; expresses at least one active US27 protein or an ortholog thereof and/or expresses at least one active US28 protein or an ortholog thereof.